ERBB2 and breast cancer: MALDI-TOF MS demonstrated that the luminal, HER2+, and TNBC subtypes of BC have different protein and lipid profiles [50], while MALDI-MSI strongly discriminated between cancer and benign tissue in TNBC, based on the identification network of proteins that could be used as biomarkers of disease recurrence in patients with this BC subtype [28].